Gene and stem cell therapy for erectile dysfunction

W. Deng, T. J. Bivalacqua, W. J.G. Hellstrom, P. J. Kadowitz

Research output: Contribution to journalReview articlepeer-review

Abstract

Erectile dysfunction (ED) is defined as the inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance. ED is a highly prevalent health problem with considerable impact on the quality of life of men and their partners. Although the treatment of ED with oral phosphodiesterase type V (PDE5) inhibitors is effective in a wide range of individuals, it is not efficacious in all patients. The failure of PDE5 inhibitors happens mainly in men with diabetes, non-nerve sparing radical prostatectomy, and high disease severity. Therefore, improved therapies based on a better understanding of the fundamental issues in erectile physiology and pathophysiology have recently been proposed. Here, we summarize studies on ED treatment using gene and stem cell therapies. Adenoviral-mediated intracavernosal transfer of therapeutic genes, such as endothelial nitric oxide synthase (eNOS), calcitonin gene-related peptide (CGRP), superoxide dismutase (SOD), and RhoA/Rho kinase and mesenchymal stem cell-based cell and gene therapy strategy for the treatment of age- and diabetes-related ED are the focus of this review.

Original languageEnglish (US)
Pages (from-to)S57-S63
JournalInternational Journal of Impotence Research
Volume17
Issue numberSUPPL. S1
DOIs
StatePublished - Dec 2005

Keywords

  • Adeno-associated virus
  • Adenovirus
  • Calcitonin gene-related peptide
  • Endothelial nitric oxide synthase
  • Erectile dysfunction
  • Gene therapy
  • RhoA/Rho kinase
  • Stem cells
  • Superoxide dismutase

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Gene and stem cell therapy for erectile dysfunction'. Together they form a unique fingerprint.

Cite this